Compare GSK plc (GSK) vs Select Medical Holdings Corporation (SEM) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day. The stock's technical outlook is mixed with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. for $16.50 per share, finalized on June 30, 2026.

The acquisition at $16.50 per share, slightly below the current price, represents a key near-term catalyst but is under legal scrutiny for potential fiduciary breaches. Analyst sentiment is cautious with a 'Hold' consensus. Risks include integration challenges post-acquisition and margin pressures, with net profit margin declining to 2.41% in 2026. The stock offers limited upside from current levels given the acquisition price cap.